Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-gamma activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A

Απλή σελίδα τεκμηρίου
dc.contributor.authorRizos, C. V.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorTellis, C. C.en
dc.contributor.authorFlorentin, M.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T19:29:15Z
dc.date.available2015-11-24T19:29:15Z
dc.identifier.issn1557-8518-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22960
dc.rightsDefault Licence-
dc.subject1-Alkyl-2-acetylglycerophosphocholine Esterase/*blood/drug effects/metabolismen
dc.subjectAgeden
dc.subjectAngiotensin II Type 1 Receptor Blockers/*administration & dosage/pharmacologyen
dc.subjectBenzimidazoles/administration & dosage/pharmacologyen
dc.subjectBenzoates/administration & dosage/pharmacologyen
dc.subjectDrug Combinationsen
dc.subjectEnzyme Activation/drug effectsen
dc.subjectFemaleen
dc.subjectFluorobenzenes/*administration & dosage/pharmacologyen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/administration &en
dc.subjectdosage/pharmacologyen
dc.subjectLipoproteins, LDL/*blood/drug effects/metabolismen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPPAR gamma/*agonists/metabolismen
dc.subjectPyrimidines/*administration & dosage/pharmacologyen
dc.subjectSulfonamides/*administration & dosage/pharmacologyen
dc.titleCombining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-gamma activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase Aen
heal.abstractBACKGROUND: Rosuvastatin reduces low-density lipoprotein cholesterol (LDL-C) and plasma lipoprotein-associated phospholipase A (Lp-PLA) Some sartans partially activate peroxisome proliferator-activated receptor-gamma (PPARgamma), possibly having a favorable effect on metabolic parameters. Telmisartan is the most potent partial PPARgamma activator, followed by irbesartan, whereas olmesartan does not hold such capacity. In an open-label randomized study, we assessed the effects of combining sartans of different PPARgamma- activating capacity with rosuvastatin on LDL subfractions and plasma Lp-PLA in patients with mixed dyslipidemia, hypertension, and prediabetes. METHODS: Following dietary intervention, patients were allocated randomly to rosuvastatin (10 mg/day) plus telmisartan 80 mg/day (RT group, n = 52) or irbesartan 300 mg/day (RI group, n = 48) or olmesartan 20 mg/day (RO group, n = 51). After 6 months of treatment, changes in LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass were evaluated blindly. RESULTS: A total of 151 patients (73 male; mean age 60 years) were included. Large LDL-C decreased in the RT (-36%), RI (-39%), and RO (-41%) groups (P < 0.001 for all vs. baseline). Small dense LDL-C decreased in the RT (-67%), RI (-58%), and RO (-61%) groups (P < 0.001 for all vs. baseline). All regimens increased LDL particle size versus baseline (RT + 1.4%, P = 0.002; RI + 1.0%, P = 0.04; and RO + 1.4%, P = 0.001). No difference for the change of LDL subfractions and LDL size was noticed among groups. Plasma Lp-PLA activity decreased equally in all groups (RT -38%, RI -38%, RO -43%) (P < 0.001 for all vs. baseline). Plasma Lp-PLA mass decreased similarly in all groups versus baseline (RT -28%, P = 0.001; RI -32%, P = 0.01; and RO -27%, P = 0.001). No difference for the change of Lp-PLA mass or activity was noticed among groups. CONCLUSIONS: The combination of rosuvastatin with sartans of different PPARgamma-activating capacity did not differentiate alterations of LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1089/met.2010.0120-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21352079-
heal.identifier.secondaryhttp://online.liebertpub.com/doi/pdfplus/10.1089/met.2010.0120-
heal.journalNameMetab Syndr Relat Disorden
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2011-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ